A fibrosis biotech has reeled in $76 million to get clinical data on three experimental medicines over the next two years.
Mediar Therapeutics raised the
Exclusive: Mediar gains $76M for clinical trials of three fibrosis drugs - Endpoints News
Mediar Therapeutics raised the Series B from its existing pharma backers as well as a collection of life sciences investors, the company exclusively told Endpoints News.
By:Kyle LaHucik
Source:Endpoints.news
Published:
Related News
A Single Molecule May Explain How Blood Flow in The Brain Triggers Dementia - ScienceAlert
Reduced blood flow to the brain is thought to be a key factor in many forms of dementia, including Alzheimer's, and scientists have just identified a new mechanism regulating this flow, which may also help explain how it goes wrong.
ScienceAlert•David Nield
Bariatric surgery beats GLP-1s for type 2 diabetes across income levels, study says - statnews.com
Across all income levels, bariatric surgery resulted in better diabetes control than GLP-1s or similar medications, a study found.
STAT•Elizabeth Cooney
21 year old Rigby man who had a 'heart of gold' continues to bless others after unexpected death - East Idaho News
RIGBY — A Rigby man, remembered for the selfless life he lived, was able to bless others through organ donation. Noel Rios, who went by the name Titus Freeman, died on the evening of Oct. 19, 2025, at the age of 21. He was riding his dirt bike — he’s been rid…
East Idaho News•Brittni Johnson